When does this change take effect?

This change is effective Mar 5, 2025.

Back to dashboard

CommercialAdministrativeLow impact

06.02.29g, AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)

Q: Who is affected by this change?

This affects Independence Blue Cross Cardiology, Cardiothoracic Surgery providers on Commercial plans.

Independence Blue Cross·Cardiology, Cardiothoracic Surgery·Pharmacy

Effective date

Mar 5, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Independence Administrators has reissued policy 06.02.29g regarding AlloMap™ Molecular Expression Testing for Heart Transplant Rejection under their pharmacy category. This is a commercial policy update that becomes effective March 5, 2025, though specific policy changes are not detailed in the summary provided.

Action Required

Action needed

By March 5, 2025: Billing team should review the full policy document at the provided URL to understand specific changes to AlloMap™ testing coverage and billing requirements for Independence Administrators commercial plans. Monitor for any prior authorization or documentation changes that may affect heart transplant patient billing.

Related policy hubs

Independence Blue Cross policies Cardiology Cardiothoracic Surgery